PA9060

PA9060 is an investigational small molecule Janus kinase (JAK) inhibitor developed by Anhui Rousidousi Pharmaceutical Technology for the topical treatment of inflammatory dermatological conditions. It is primarily being evaluated for the treatment of eczema, neurodermatitis, and pruritus. By inhibiting the JAK-STAT signaling pathway, PA9060 modulates the production and signaling of pro-inflammatory cytokines and itch-inducing molecules that drive the pathogenesis of these skin disorders. The drug is formulated as an ointment for local application, a strategy intended to achieve high therapeutic concentrations at the site of inflammation while minimizing systemic absorption and the potential for systemic side effects typically associated with oral JAK inhibitors.